MTP - マイダテック・ファ―マ (Midatech Pharma PLC) マイダテック・ファ―マ

 MTPのチャート


 MTPの企業情報

symbol MTP
会社名 Midatech Pharma PLC (マイダテック・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company''s segments include Pipeline Research and Development and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms. The Commercial segment distributes and sells the commercial products. Its products include Zuplenz Gelclair Oravig and Soltamox. Zuplenz is an oral soluble film indicated for moderately emetogenic chemotherapy-induced nausea and vomiting (CINV) radiotherapy-induced nausea and vomiting (RINV) and post-operative nausea and vomiting (PONV). Gelclair is a product indicated for the management and relief of pain due to oral mucositis. Oravig is an orally dissolving buccal tablet approved for oral thrush. Soltamox is an oral liquid solution of tamoxifen citrate for the prevention of breast cancer.   マイダテック・ファ―マはイギリスの医療系持株会社。子会社を通じ、ナノ化薬物の持続放出技術を用いた治療薬の開発と商業化に従事。主に糖尿病、肝臓がん、卵巣がん、悪性脳腫瘍、及び神経系や眼系の病気に対する治療において、適切なタイミングで、適切な患部に薬物を送達したり、既存薬の持続放出を可能にさせる。本社はアビングドン。   
本社所在地 65 Innovation Drive Milton Park Abingdon Oxfordshire OX14 4RQ GBR
代表者氏名
代表者役職名
電話番号
設立年月日 41883
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 85人
url www.midatechpharma.com
nasdaq_url https://www.nasdaq.com/symbol/mtp
adr_tso 2920413
EBITDA EBITDA ー
終値(lastsale) 0.58
時価総額(marketcap) 1693839.54
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 MTPのテクニカル分析


 MTPのニュース

   Why Is Midatech Pharma (BDRX) Stock Up 64% Today?  2023/03/28 12:34:55 InvestorPlace
Midatech Pharma (BDRX) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new research program.
   Midatech Pharma - £5m fund-raise to provide headroom to end-FY23  2023/02/13 11:34:00 Finanz Nachrichten
Midatech announced on 9 February a private placement to certain US institutional investors to raise US$6m (£5m) in gross proceeds. The issue will comprise 10.3m ADS units (or ADS-equivalent pre-fun…
   Midatech gets non-compliance notice from Nasdaq  2023/02/03 11:17:26 Seeking Alpha
Midatech Pharma (MTP) received a notice from Nasdaq for not being in compliance with the $1 minimum bid price requirement rule for continued listing on the exchnage.The…
   Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc  2023/01/23 14:22:00 GlobeNewswire
NEW HAVEN, Conn., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI) (the “ Company ” or “ Bioasis ”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB 3 ™ platform for delivering therapeutics across the blood-brain barrier (“ BBB ”) and the treatment of central nervous system (“ CNS ”) disorders in areas of high unmet medical need, today announced that it has terminated the arrangement agreement (the “ Arrangement Agreement ”) dated December 13, 2022, as amended December 18, 2022, between Bioasis and Midatech Pharma plc (“ Midatech ”). The Arrangement Agreement provided for Midatech’s acquisition of all of Bioasis’ issued and outstanding shares in exchange for ordinary shares of Midatech by way of a statutory plan of arrangement under the laws of British Columbia (the “ Arrangement ”).
   Midatech Pharma Shares Rise on Revised Placement Terms, Intention to Remain on AIM  2022/12/19 09:24:00 MarketWatch
By Anthony O. Goriainoff Shares in Midatech Pharma PLC rose Monday after the company said it had agreed to revise the terms of a private placement, and that…
   Why Is Midatech Pharma (BDRX) Stock Up 64% Today?  2023/03/28 12:34:55 InvestorPlace
Midatech Pharma (BDRX) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new research program.
   Midatech Pharma - £5m fund-raise to provide headroom to end-FY23  2023/02/13 11:34:00 Finanz Nachrichten
Midatech announced on 9 February a private placement to certain US institutional investors to raise US$6m (£5m) in gross proceeds. The issue will comprise 10.3m ADS units (or ADS-equivalent pre-fun…
   Midatech gets non-compliance notice from Nasdaq  2023/02/03 11:17:26 Seeking Alpha
Midatech Pharma (MTP) received a notice from Nasdaq for not being in compliance with the $1 minimum bid price requirement rule for continued listing on the exchnage.The…
   Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc  2023/01/23 14:22:00 GlobeNewswire
NEW HAVEN, Conn., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI) (the “ Company ” or “ Bioasis ”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB 3 ™ platform for delivering therapeutics across the blood-brain barrier (“ BBB ”) and the treatment of central nervous system (“ CNS ”) disorders in areas of high unmet medical need, today announced that it has terminated the arrangement agreement (the “ Arrangement Agreement ”) dated December 13, 2022, as amended December 18, 2022, between Bioasis and Midatech Pharma plc (“ Midatech ”). The Arrangement Agreement provided for Midatech’s acquisition of all of Bioasis’ issued and outstanding shares in exchange for ordinary shares of Midatech by way of a statutory plan of arrangement under the laws of British Columbia (the “ Arrangement ”).
   Midatech Pharma Shares Rise on Revised Placement Terms, Intention to Remain on AIM  2022/12/19 09:24:00 MarketWatch
By Anthony O. Goriainoff Shares in Midatech Pharma PLC rose Monday after the company said it had agreed to revise the terms of a private placement, and that…
   Midatech Pharma reports FY results  2022/04/26 06:46:49 Seeking Alpha
Midatech Pharma press release (MTP): FY Cash and deposits at 31 December 2021 of £10.06M (2020: £7.55M).Net loss from continuing operations of £5.46M (2020: £22.19M loss).Net cash…
   Midatech Pharma PLC Announces Results for the Year Ended 31 December 2021  2022/04/26 06:00:00 Wallstreet:Online
ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 26, 2022 / Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces its audited preliminary results for the …
   Midatech Pharma receives noncompliance notice from Nasdaq  2022/04/14 12:43:10 Seeking Alpha
Midatech Pharma (MTP) received a letter from the Listings Qualifications Department of the Nasdaq that it is not in compliance with the minimum bid price.The notification does not lead…
   Midatech Pharma PLC Announces Receipt of NASDAQ Notice  2022/04/14 12:10:00 Wallstreet:Online
ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 14, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received written …
   J&J extends R&D collaboration with Midatech Pharma on second molecule (NYSE:JNJ)  2022/03/10 17:10:40 Seeking Alpha
Johnson & Johnson (JNJ) Janssen unit and U.K.-based Midatech Pharma are extending a research collaboration to include a second molecule.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 マイダテック・ファ―マ MTP Midatech Pharma PLC)

 twitter  (公式ツイッターやCEOツイッターなど)